Clinical and Biomarker Outcomes of the Phase II Vandetanib Study From the BATTLE Trial

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e31828d08ae
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pharmacogenetic Study of the Impact of ABCB1 Single-Nucleotide Polymorphisms on Lenalidomide Treatment Outcomes in Patients With Multiple Myeloma: Results From a Phase IV Observational Study and Subsequent Phase II Clinical Trial

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2017English

Phase II Cancer Clinical Trials for Biomarker-Guided Treatments

Journal of Biopharmaceutical Statistics
StatisticsProbabilityPharmacology
2017English

Cytomegalovirus Vaccine: Phase II Clinical Trial Results

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2014English

Phase II Trial of Karenitecin in Patients With Malignant Melanoma: Clinical and Translational Study

Clinical Cancer Research
Cancer ResearchOncology
2005English

Treatment–subgroup Interaction: An Example From a Published, Phase II Clinical Trial

Contemporary Clinical Trials
MedicinePharmacology
2009English

SBRT for Early-Stage Glottic Larynx Cancer—Initial Clinical Outcomes From a Phase I Clinical Trial

PLoS ONE
Multidisciplinary
2017English

Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants

Oncologist
Cancer ResearchMedicineOncology
2019English

ERCC1 Is a Prognostic Biomarker in Locally Advanced Head and Neck Cancer: Results From a Randomised, Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2013English

TROG 15.03 Phase II Clinical Trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy